Xu R - Search Results

1

Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.

Li J, Xu R, Qin S, Liu T, Pan H, Xu J, Bi F, Lim R, Zhang S, Ba Y, Bai Y, Fan N, Tsuji A, Yeh KH, Ma B, Wei V, Shi D, Magherini E, Shen L. Li J, et al. Among authors: xu r, xu j. Future Oncol. 2018 Aug;14(20):2031-2044. doi: 10.2217/fon-2017-0669. Epub 2018 Aug 17. Future Oncol. 2018. PMID: 30117334 Clinical Trial.

2

[Phase II clinical trial of oxaliplatin alone for refractory advanced colorectal cancer].

Xu RH, Guan ZZ, Feng FY, He XH, Liu SJ, Di LJ, Li SF, Li LQ. Xu RH, et al. Ai Zheng. 2003 Aug;22(8):874-6. Ai Zheng. 2003. PMID: 12917039 Clinical Trial. Chinese.

3

[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].

Luo HY, Li YH, Zhang L, Jiang WQ, Shi YX, Wang F, He YJ, Xu RH. Luo HY, et al. Ai Zheng. 2007 Aug;26(8):905-8. Ai Zheng. 2007. PMID: 17697557 Free article. Chinese.

4

A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.

Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ. Luo HY, et al. Chemotherapy. 2008;54(3):228-35. doi: 10.1159/000140467. Epub 2008 Jun 18. Chemotherapy. 2008. PMID: 18560231 Clinical Trial.

5

[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].

Li YH, Wang FH, Zhang DS, Wang ZQ, Feng F, Zhang L, Xu RH, Jiang WQ, He YJ. Li YH, et al. Ai Zheng. 2009 Sep;28(9):913-8. doi: 10.5732/cjc.008.10571. Ai Zheng. 2009. PMID: 19728906 Free article. Clinical Trial. Chinese.

6

[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].

Li YH, An X, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH. Li YH, et al. Ai Zheng. 2009 Sep;28(9):939-44. doi: 10.5732/cjc.009.10001. Ai Zheng. 2009. PMID: 19728911 Free article. Chinese.

7

Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.

Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ, Xu RH. Li YH, et al. J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. doi: 10.1007/s00432-009-0682-5. Epub 2009 Sep 24. J Cancer Res Clin Oncol. 2010. PMID: 19777259 Clinical Trial.

8

Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.

An X, Ding PR, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH, Li YH. An X, et al. Biomarkers. 2010 May;15(3):243-8. doi: 10.3109/13547500903477377. Biomarkers. 2010. PMID: 20121626

9

Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.

Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, Zhou ZW, Chen XQ. Luo HY, et al. Chemotherapy. 2010;56(2):94-100. doi: 10.1159/000305256. Epub 2010 Mar 30. Chemotherapy. 2010. PMID: 20357440 Clinical Trial.

10

EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.

Li YH, Wang F, Shen L, Deng YM, Shao Q, Feng F, An X, Wang FH, Wang ZQ, Xu RH, Shao JY. Li YH, et al. Clin Cancer Res. 2011 Jan 15;17(2):382-90. doi: 10.1158/1078-0432.CCR-10-0208. Epub 2010 Sep 30. Clin Cancer Res. 2011. PMID: 20884623

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,449 results

Search Page

Filters